$ASNS
ACTELIS NETWORKS INC Stock $asns

$asns Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023087004 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$1.017M	$845.0K	$2.534M
YoY Change	-59.87%	-37.31%
Cost Of Revenue	$663.0K	$619.0K	$1.463M
YoY Change	-54.68%	-23.86%
Gross Profit	$354.0K	$226.0K	$1.071M
YoY Change	-66.95%	-57.76%
Gross Profit Margin	34.81%	26.75%	42.27%
Selling, General & Admin	$1.424M	$1.662M	$2.358M
YoY Change	-39.61%	-8.58%
% of Gross Profit	402.26%	735.4%	220.17%
Research & Development	$585.0K	$691.0K	$717.0K
YoY Change	-18.41%	-4.43%
% of Gross Profit	165.25%	305.75%	66.95%
Depreciation & Amortization	$7.000K	$10.00K	-$6.000K
YoY Change	-216.67%	11.11%
% of Gross Profit	1.98%	4.42%	-0.56%
Operating Expenses	$2.009M	$2.353M	$3.075M
YoY Change	-34.67%	-7.4%
Operating Profit	-$1.655M	-$2.127M	-$2.004M
YoY Change	-17.42%	6.03%
Interest Expense	-$276.0K	$161.0K	-$478.0K
YoY Change	-42.26%	-180.1%
% of Operating Profit
Other Income/Expense, Net		$0.00
YoY Change		-100.0%
Pretax Income	-$1.931M	-$870.0K	-$2.482M
YoY Change	-22.2%	-60.58%
Income Tax
% Of Pretax Income
Net Earnings	-$1.931M	-$867.0K	-$2.482M
YoY Change	-22.2%	-60.72%
Net Earnings / Revenue	-189.87%	-102.6%	-97.95%
Basic Earnings Per Share		-$0.32
Diluted Earnings Per Share	-$0.67	-$0.32	-$0.14
COMMON SHARES
Basic Shares Outstanding	2.716M shares	2.708M shares	17.32M shares
Diluted Shares Outstanding		2.686M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$817.0K	$940.0K	$5.565M
YoY Change	-85.32%	-90.85%
Cash & Equivalents	$620.0K	$682.0K	$3.943M
Short-Term Investments	$197.0K	$250.0K	$1.622M
Other Short-Term Assets	$1.905M	$1.070M	$1.129M
YoY Change	68.73%	-17.63%
Inventory	$2.526M	$2.698M	$1.179M
Prepaid Expenses	$198.0K		$473.0K
Receivables	$664.0K	$720.0K	$3.034M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.912M	$5.415M	$10.91M
YoY Change	-45.8%	-63.28%	163.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$61.00K	$66.00K	$80.00K
YoY Change	-23.75%	-38.89%	-22.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.250M	$5.680M	$3.832M
YoY Change	37.0%	285.87%
Total Long-Term Assets	$5.311M	$5.743M	$3.912M
YoY Change	35.76%	263.48%	612.57%
TOTAL ASSETS
Total Short-Term Assets	$5.912M	$5.415M	$10.91M
Total Long-Term Assets	$5.311M	$5.743M	$3.912M
Total Assets	$11.22M	$11.16M	$14.82M
YoY Change	-24.27%	-31.65%	216.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.769M	$2.190M	$1.781M
YoY Change	-0.67%	156.74%
Accrued Expenses	$2.682M	$2.080M	$1.190M
YoY Change	125.38%	-2.53%	46.37%
Deferred Revenue	$389.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.335M	$1.229M	$553.0K
YoY Change	141.41%	58.17%	-27.04%
Total Short-Term Liabilities	$6.912M	$6.631M	$6.202M
YoY Change	11.45%	18.6%	4.22%
LONG-TERM LIABILITIES
Long-Term Debt	$3.154M	$3.180M	$4.625M
YoY Change	-31.81%	-27.3%
Other Long-Term Liabilities	$769.0K	$25.00K	$727.0K
YoY Change	5.78%	-51.92%	820.25%
Total Long-Term Liabilities	$3.923M	$3.585M	$5.352M
YoY Change	-26.7%	-30.67%	-58.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.912M	$6.631M	$6.202M
Total Long-Term Liabilities	$3.923M	$3.585M	$5.352M
Total Liabilities	$10.84M	$10.22M	$11.55M
YoY Change	-6.22%	-5.07%	-38.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$39.69M	-$37.76M	-$33.40M
YoY Change	18.82%	22.11%	48.98%
Common Stock	$39.92M	$38.60M	$1.000K
YoY Change	3991600.0%	3859400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$388.0K	$838.0K	$3.265M
YoY Change
Total Liabilities & Shareholders Equity	$11.22M	$11.16M	$14.82M
YoY Change	-24.27%	-31.65%	216.37%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.931M	-$867.0K	-$2.482M
YoY Change	-22.2%	-60.72%
Depreciation, Depletion And Amortization	$7.000K	$10.00K	-$6.000K
YoY Change	-216.67%	11.11%
Cash From Operating Activities	-$1.387M	-$2.250M	-$1.992M
YoY Change	-30.37%	12.84%
INVESTING ACTIVITIES
Capital Expenditures	-$1.000K	$10.00K	-$34.00K
YoY Change	-97.06%	-155.56%
Acquisitions
YoY Change
Other Investing Activities	$2.390M	$760.0K	-$3.966M
YoY Change	-160.26%	25233.33%
Cash From Investing Activities	$2.391M	$750.0K	-$3.932M
YoY Change	-160.81%	-5100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.171M	-190.0K	-742.0K
YoY Change	-257.82%	-1.55%
NET CHANGE
Cash From Operating Activities	-1.387M	-2.250M	-1.992M
Cash From Investing Activities	2.391M	750.0K	-3.932M
Cash From Financing Activities	1.171M	-190.0K	-742.0K
Net Change In Cash	2.175M	-1.690M	-6.666M
YoY Change	-132.63%	-23.25%
FREE CASH FLOW
Cash From Operating Activities	-$1.387M	-$2.250M	-$1.992M
Capital Expenditures	-$1.000K	$10.00K	-$34.00K
Free Cash Flow	-$1.386M	-$2.260M	-$1.958M
YoY Change	-29.21%	14.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1731753	shares
CY2023Q3	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount		usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount		usd
	asns	Long Term Restricted Bank Deposits LongTermRestrictedBankDeposits		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41375
	dei	Entity Registrant Name EntityRegistrantName	ACTELIS NETWORKS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-2160309
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4039 Clipper Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
	dei	City Area Code CityAreaCode	(510)
	dei	Local Phone Number LocalPhoneNumber	545-1045
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	ASNS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2716436	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	682000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023Q3	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	450000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3943000	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	254000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	1622000	usd
CY2022Q4	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	451000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	125000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	125000	usd
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	715000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3034000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2698000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1179000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	616000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	678000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	5415000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10907000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	66000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2023Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	592000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	492000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2407000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	336000	usd
CY2023Q3	us-gaap	Other Restricted Assets Noncurrent OtherRestrictedAssetsNoncurrent	2036000	usd
CY2022Q4	us-gaap	Other Restricted Assets Noncurrent OtherRestrictedAssetsNoncurrent	2027000	usd
CY2023Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	225000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	239000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	403000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	726000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	14000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	12000	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	5743000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3912000	usd
CY2023Q3	us-gaap	Assets Assets	11158000	usd
CY2022Q4	us-gaap	Assets Assets	14819000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1229000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	553000	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8000	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2192000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1781000	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	386000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	484000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	732000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	793000	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	924000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	900000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	255000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	445000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	905000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1238000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6631000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6202000	usd
CY2023Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	3175000	usd
CY2022Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	4625000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	164000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	237000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	256000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	278000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	25000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3585000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5352000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	10216000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	11554000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	asns	Warrants To Placement Agent WarrantsToPlacementAgent	104000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11158000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14819000	usd
CY2023Q3	us-gaap	Revenues Revenues	845000	usd
CY2022Q3	us-gaap	Revenues Revenues	1348000	usd
	us-gaap	Revenues Revenues	4589000	usd
	us-gaap	Revenues Revenues	6297000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	619000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	813000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3043000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3258000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	226000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	535000	usd
	us-gaap	Gross Profit GrossProfit	1546000	usd
	us-gaap	Gross Profit GrossProfit	3039000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	691000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	723000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2117000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2049000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	691000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	790000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2332000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2357000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	971000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1028000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2805000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2730000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2353000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2541000	usd
	us-gaap	Operating Expenses OperatingExpenses	7254000	usd
	us-gaap	Operating Expenses OperatingExpenses	7136000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2127000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2006000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5708000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4097000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	161000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	198000	usd
	us-gaap	Interest Expense InterestExpense	512000	usd
	us-gaap	Interest Expense InterestExpense	622000	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1421000	usd
CY2022Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-3000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1865000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-3781000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-867000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2207000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4355000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8500000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.77
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2685626	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2254235	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	968721	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-19596000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4639000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-24221000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14000	usd
CY2022Q2	asns	Stock Issued During Period Value Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering	5585000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	14675000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	6553000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3600000	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	3190000	usd
CY2022Q2	asns	Repurchase Of Common Stock RepurchaseOfCommonStock	-15000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1654000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7757000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	13000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2207000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5563000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3265000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	95000	usd
CY2023Q1	asns	Repurchase Of Common Stock RepurchaseOfCommonStock	50000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1895000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1415000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	97000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1356000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1593000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1285000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	106000	usd
CY2023Q3	asns	Reclassification Of Warrants From Liabilities To Equity ReclassificationOfWarrantsFromLiabilitiesToEquity	314000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-867000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	838000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4355000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8500000	usd
	us-gaap	Depreciation Depreciation	20000	usd
	us-gaap	Depreciation Depreciation	29000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1658000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1068000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	223000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	132000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	106000	usd
	asns	Exchange Rate Differences ExchangeRateDifferences	-365000	usd
	asns	Exchange Rate Differences ExchangeRateDifferences	-798000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	298000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	41000	usd
	asns	Changes In Fair Value Related To Convertible Loan ChangesInFairValueRelatedToConvertibleLoan	1648000	usd
	asns	Changes In Fair Value Related To Convertible Note ChangesInFairValueRelatedToConvertibleNote	1753000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	78000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2319000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-37000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-25000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	62000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1651000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	271000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-62000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	251000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	100000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	245000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	411000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1067000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-262000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	145000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-185000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	406000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-30000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	185000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5194000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5776000	usd
	asns	Short Term Deposits ShortTermDeposits	1363000	usd
	asns	Short Term Deposits ShortTermDeposits	-68000	usd
	asns	Long Term Restricted Bank Deposits LongTermRestrictedBankDeposits	75000	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	2000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1430000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-102000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3500000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	18712000	usd
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	291000	usd
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2175000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	583000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	509000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2586000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16028000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-12000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1190000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10150000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4279000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	795000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3089000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10945000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	682000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	10206000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	650000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2407000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	89000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3089000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10945000	usd
	us-gaap	Interest Paid Net InterestPaidNet	512000	usd
	us-gaap	Interest Paid Net InterestPaidNet	626000	usd
	asns	Issuance Costs Of Common Stock Prefunded Warrants And Warrants IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants	104000	usd
	us-gaap	Stock Issued1 StockIssued1	314000	usd
	us-gaap	Interest Costs Incurred InterestCostsIncurred	4355000	usd
CY2022	us-gaap	Interest Costs Incurred InterestCostsIncurred	10982000	usd
	asns	Negative Cash Flows From Operations NegativeCashFlowsFromOperations	5194000	usd
CY2022	asns	Negative Cash Flows From Operations NegativeCashFlowsFromOperations	7768000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37757000	usd
	us-gaap	Dividends Cash DividendsCash	1386000	usd
CY2023Q3	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	4457000	usd
CY2022Q2	asns	Aggregate Shares AggregateShares	421250	shares
CY2022Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	46250	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	40
	asns	Netproceeds Netproceeds	15400000	usd
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1000000	usd
CY2023Q3	asns	Warrants Exercisable Price WarrantsExercisablePrice	29487	shares
CY2023Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	145000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">b)</td><td style="text-align: left"><b>Use of estimates in preparation of financial statements </b></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
	asns	Convertible Note Offering Amount ConvertibleNoteOfferingAmount	3000000	usd
	asns	Convertible Note Offering Percentage ConvertibleNoteOfferingPercentage	0.06	pure
CY2022Q1	asns	Convertible Note Offered ConvertibleNoteOffered	3000000	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	60000	usd
	us-gaap	Product Warranty Expense ProductWarrantyExpense	8000	usd
CY2022	us-gaap	Product Warranty Expense ProductWarrantyExpense	8000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">e)</span></td><td style="text-align: justify"><b>Concentration of risk</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and trade receivables. Cash and cash equivalents and restricted cash are placed with banks and financial institutions in the United States and Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has major customers, representing as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer A represented <span style="-sec-ix-hidden: hidden-fact-193">2</span></span>4<span style="font-family: Times New Roman, Times, Serif">% and </span>3<span style="font-family: Times New Roman, Times, Serif">% of the Company Trade receivables balance as of September 30, 2023, and December 31, 2022, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer B represented 24% and 5% of the Company Trade receivables balance as of September 30, 2023, and December 31, 2022, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify">Customer C represented 0% and 29% of the Company Trade receivables balance as of September 30, 2023, and December 31, 2022, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">Customer D represented 0% and 23% of the Company Trade receivables balance as of September 30, 2023, and December 31, 2022, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">Customer E represented 0% and 10% of the Company Trade receivables balance as of September 30, 2023, and December 31, 2022, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"></td><td style="text-align: justify">The Company does not see any credit risk regarding the major trade receivable balance, as most of the remaining balance was paid off after the balance sheet date.</td> </tr></table>
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On April 15, 2022, the Company’s Board of Directors approved a Reverse Stock Split in the ratio of forty-six to-one.
CY2023Q3	us-gaap	Debt Instrument Convertible Liquidation Preference Value DebtInstrumentConvertibleLiquidationPreferenceValue	50000	usd
	asns	Conversion Notes Payable ConversionNotesPayable	1.10	pure
CY2023Q3	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	8000	usd
CY2022Q4	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	8000	usd
CY2023Q3	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	1330000	usd
	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	1726000	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	764	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	593	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1934	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	586	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	2698	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	1179	usd
	us-gaap	Inventory Write Down InventoryWriteDown	132000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	106000	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	35000	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	26000	usd
CY2023Q2	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
CY2020Q3	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	150000	usd
CY2020Q4	asns	New Loan NewLoan	20000000	ils
CY2020Q4	asns	New Loan NewLoan	6000000	usd
CY2020Q4	us-gaap	Financing Receivable Loan In Process FinancingReceivableLoanInProcess	3000000	usd
CY2021Q1	asns	Additional Loan Value AdditionalLoanValue	2000000	usd
	asns	Adjustment Of Warrants Granted For Service AdjustmentOfWarrantsGrantedForService	1500000	usd
CY2021Q4	asns	Additional Funding Amount Of New Lender AdditionalFundingAmountOfNewLender	1000000	usd
CY2023Q3	asns	Warrant Issued WarrantIssued	1800000	usd
CY2023Q3	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Outstanding Balance CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesOutstandingBalance	4249000	usd
CY2023Q3	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	1220000	usd
CY2023Q3	us-gaap	Deposits Deposits	2000000	usd
CY2023Q3	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	2000000	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-1726000	usd
CY2022	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	1049000	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	68000	usd
CY2022Q4	asns	Conversion To The Companys Common Stock ConversionToTheCompanysCommonStock	-3190000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	314000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2	ils
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	921	ils
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	241000	usd
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	234	ils
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	61000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	9	ils
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	5567	ils
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1456000	usd
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1080	ils
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	282000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9	ils
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3684	ils
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	963000	usd
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	704	ils
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	184000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	9	ils
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3684	ils
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	963000	usd
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	704	ils
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	184000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9	ils
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3684	ils
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	963000	usd
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	704	ils
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	184000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	130	ils
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	307	ils
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	80000	usd
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	59	ils
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	15000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-12	ils
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4123	ils
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1077000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	961	ils
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	250000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	156	ils
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	13724	ils
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	3589000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	2524	ils
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	660000	usd
CY2023Q3	asns	Exchange Rate ExchangeRate	1
CY2023Q3	asns	Exchange Rate ExchangeRate	3.824
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	1847000	usd
CY2022	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	1753000	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3600000	usd
CY2023Q3	us-gaap	Other Expenses OtherExpenses	0	usd
	us-gaap	Other Expenses OtherExpenses	0	usd
CY2022Q3	us-gaap	Other Expenses OtherExpenses	0	usd
	us-gaap	Other Expenses OtherExpenses	1753000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4905	usd
CY2022	asns	Change In Fair Value Reported In Statement Of Comprehensive Loss ChangeInFairValueReportedInStatementOfComprehensiveLoss	1648	usd
CY2022	asns	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued	6553	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1648000	usd
CY2022Q4	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	8000	usd
CY2021Q4	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	2149000	usd
	us-gaap	Additions To Other Assets Amount AdditionsToOtherAssetsAmount	1972000	usd
	asns	Warrants Exercise Percentage WarrantsExercisePercentage	1.25	pure
CY2022Q3	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	47000	usd
	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	1068000	usd
	us-gaap	Credit Derivative Liquidation Proceeds Percentage CreditDerivativeLiquidationProceedsPercentage	1	pure
CY2023Q3	us-gaap	Other Receivables OtherReceivables	14300000	usd
CY2023Q3	us-gaap	Interest Receivable InterestReceivable	15668000	usd
	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	10275000	usd
	asns	Due Amount DueAmount	73000	usd
CY2022	asns	Due Amount DueAmount	221000	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	924000	usd
CY2022	us-gaap	Payments For Royalties PaymentsForRoyalties	900000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2022Q2	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	10000000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	7920	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	7920	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10690	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10690	shares
CY2023Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	3500000	usd
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	190000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	754670	shares
CY2023Q2	asns	Prefunded Warrants PrefundedWarrants	754670	shares
CY2023Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.0001
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	246000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.54	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.046	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P5Y1M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.1
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1330000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1726000	usd
CY2023Q3	us-gaap	Other General Expense OtherGeneralExpense	68000	usd
	us-gaap	Other General Expense OtherGeneralExpense	68000	usd
CY2023Q3	asns	Exercise Of Prefunded Warrant ExerciseOfPrefundedWarrant	754670	shares
CY2023Q3	asns	Exercise Of Prefunded Warrant ExerciseOfPrefundedWarrant	754670	shares
CY2023Q3	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.0755
CY2023Q3	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.0755
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	291000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	66127	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.6313
CY2023Q3	us-gaap	General Partners Offering Costs GeneralPartnersOfferingCosts	223000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	172000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	96458	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.89
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M2D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2489	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.9
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	3992	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.16
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	90377	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.94
	asns	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y5M8D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	77759	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.23
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M6D
CY2023Q3	us-gaap	Shares Issued SharesIssued	39100	shares
CY2022Q4	asns	Share Based Compensation Arrangement By Outstanding Numbers ShareBasedCompensationArrangementByOutstandingNumbers	59200	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	16.2
	asns	Share Based Compensation Arrangement By Share Based Payment Options Grants ShareBasedCompensationArrangementByShareBasedPaymentOptionsGrants	39100	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.38
CY2023Q3	asns	Share Based Compensation Arrangements Weighted Average Exercise Price ShareBasedCompensationArrangementsWeightedAverageExercisePrice	-16954	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	18.1
	asns	Share Based Compensation Arrangement By Forfeited ShareBasedCompensationArrangementByForfeited	-8400	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	4.8
CY2023Q3	asns	Share Based Compensation Arrangement By Outstanding Numbers ShareBasedCompensationArrangementByOutstandingNumbers	72945	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.1
	asns	Convertible Common Stock Outstanding ConvertibleCommonStockOutstanding	90377	shares
	asns	Convertible Common Stock Outstanding ConvertibleCommonStockOutstanding	94018	shares
	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3.94
	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	4.53
CY2023Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	72945	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.1
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-867000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2207000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4355000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8500000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	2370486	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1731753	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1986178	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	968721	shares
CY2023Q3	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares	304250	shares
	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares	262712	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	10890	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	5345	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2685626	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1731753	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2254235	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	968721	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q3	us-gaap	Revenues Revenues	845000	usd
CY2022Q3	us-gaap	Revenues Revenues	1348000	usd
	us-gaap	Revenues Revenues	4589000	usd
	us-gaap	Revenues Revenues	6297000	usd
CY2023Q3	asns	Contract With Customer Liability Revenue Recognize ContractWithCustomerLiabilityRevenueRecognize	648000	usd
CY2022Q4	asns	Contract With Customer Liability Revenue Recognize ContractWithCustomerLiabilityRevenueRecognize	673000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-494000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-593000	usd
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	232000	usd
CY2022	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	568000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	386000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	648000	usd
CY2023Q3	us-gaap	Purchase Obligation PurchaseObligation	386000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2017Q1	us-gaap	Convertible Debt ConvertibleDebt	26000	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	59200	shares
CY2022Q4	asns	Directors Shares Transaction DirectorsSharesTransaction	10000	shares
CY2023Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q3	asns	Exercise Of Prefunded Warrants Into Common Stock ExerciseOfPrefundedWarrantsIntoCommonStock		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	asns	Changes In Fair Value Related To Convertible Loan ChangesInFairValueRelatedToConvertibleLoan		usd
	asns	Changes In Fair Value Related To Convertible Note ChangesInFairValueRelatedToConvertibleNote		usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue		usd
	asns	Issuance Costs Of Common Stock Prefunded Warrants And Warrants IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs		usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs		usd
CY2022Q2	us-gaap	Long Term Debt Term LongTermDebtTerm	P3Y
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2022	us-gaap	Additions To Other Assets Amount AdditionsToOtherAssetsAmount		usd
CY2023Q3	asns	Conversion To The Companys Common Stock ConversionToTheCompanysCommonStock		usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued		usd
CY2022Q3	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares		shares
	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares		shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1731753	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2254235	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2685626	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	968721	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001141284

Files In Submission

Name	View Source	Status
asns-20230930_def.xml	Edgar Link	unprocessable
asns-20230930_pre.xml	Edgar Link	unprocessable
asns-20230930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
asns-20230930_lab.xml	Edgar Link	unprocessable
0001213900-23-087004-index-headers.html	Edgar Link	pending
0001213900-23-087004-index.html	Edgar Link	pending
0001213900-23-087004.txt	Edgar Link	pending
0001213900-23-087004-xbrl.zip	Edgar Link	pending
asns-20230930.xsd	Edgar Link	pending
f10q0923ex31-1_actelisnet.htm	Edgar Link	pending
f10q0923ex31-2_actelisnet.htm	Edgar Link	pending
f10q0923ex32-1_actelisnet.htm	Edgar Link	pending
f10q0923ex32-2_actelisnet.htm	Edgar Link	pending
f10q0923_actelisnet.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
f10q0923_actelisnet_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASNS
ACTELIS NETWORKS INC Stock $asns

2023 Q4 Form 10-Q Financial Statement

#000121390023087004 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASNS ACTELIS NETWORKS INC Stock $asns

2023 Q4 Form 10-Q Financial Statement

#000121390023087004 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASNS
ACTELIS NETWORKS INC Stock $asns